AP
XLRN

AGTC Partners’s Acceleron Pharma XLRN Stock Holding History

AGTC Partners’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		$13.2M Hold
530,919
– – 97.39% 1
2015
Q2 		$16.8M Hold
530,919
– – 90.87% 1
2015
Q1 		$20.2M Hold
530,919
– – 89.05% 1
2014
Q4 		$20.7M Buy
+530,919
New +$18.5M 93.61% 1

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
PVMCI
Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

AGTC Partners's XLRN Position: Q3 2015 in Review

AGTC Partners held its Acceleron Pharma (XLRN) position steady in Q3 2015 at 530,919 shares worth $13.2M. The position accounts for 97.39% of the portfolio, ranked #1.

AGTC Partners first reported a position in XLRN in Q4 2014 and has held it in 4 quarters since. The position peaked at $20.7M in Q4 2014. 111 funds tracked by Wall St. Rank hold XLRN as of Q3 2015.

  • AGTC Partners held 530,919 shares of Acceleron Pharma worth $13.2M as of Q3 2015.
  • AGTC Partners left its Acceleron Pharma share count unchanged in Q3 2015.
  • Acceleron Pharma made up 97.39% of AGTC Partners's portfolio in Q3 2015, its #1 holding.
  • AGTC Partners first reported a position in Acceleron Pharma in Q4 2014 and has held it in 4 quarters since.
  • AGTC Partners's Acceleron Pharma position peaked at $20.7M in Q4 2014.
  • 111 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2015.

Based on AGTC Partners's 13F filing for Q3 2015, filed 13 Nov 2015.